WASHINGTON, April 22, 2013 /PRNewswire-USNewswire/ -- The American College of Cardiology Board of Trustees today announced that Shalom "Shal" Jacobovitz has been selected as the college's chief executive officer.
"Shal has a track record that demonstrates he is the right person to lead a strong organization like the ACC and to take it to the next level at a time when health care is undergoing massive changes," said ACC President John Gordon Harold , MD, MACC. "He is an innovative and proven leader as well as a successful mentor and team builder. Shal brings a unique perspective at a time when the College is ramping up to meet the evolving needs of cardiovascular professionals domestically and around the globe."
Jacobovitz comes to the ACC from Actelion Pharmaceuticals U.S., a biopharmaceutical company specializing in cardio-pulmonary therapies, where he has served as president since 2004. At Actelion, Jacobovitz developed a strong patient- and customer-centered corporate strategy, which he implemented globally.
"This is an exciting time for the College," said former ACC President William Zoghbi , MD, MACC, who led the CEO Search Committee. "Shal comes to the ACC with more than 25 years in health care, including extensive international and domestic experience. He shares the College's commitment to quality, innovation and strategic management, and we are confident he will advance the ACC's mission to transform cardiovascular care and improve heart health."
Prior to Actelion, Jacobovitz held positions at F. Hoffmann La Roche, where he served as general manager for Central America and the Caribbean, led the Pharmaceutical, OTC and Diagnostic divisions, and served as the g
|SOURCE American College of Cardiology|
Copyright©2012 PR Newswire.
All rights reserved